Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
NCT06980259 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106
Last updated 2026-04-28
Summary
This study is a multicenter, prospective, randomized controlled phase II clinical trial designed to evaluate the efficacy and safety of Spatially Fractionated Radiation Therapy (SFRT) compared to Conventional Radiation Therapy (CRT) in the treatment of soft tissue sarcoma (STS, minimum tumor diameter ≥5 cm). A total of 106 patients were enrolled and randomized in a 1:1 ratio. The primary endpoint is the objective response rate (ORR) of the target lesion at 3, 6, 9, and 12 months post-radiotherapy, assessed using RECIST 1.1 and Choi criteria. Secondary endpoints include the 1-year local control rate (LC) of the target lesion, progression-free survival (PFS), safety (per CTCAE v5.0), and quality of life (QoL, assessed by EORTC QLQ-C30). CRT is delivered at 3.0 Gy per fraction for a total of 15-20 fractions. SFRT comprises CRT at 3.0 Gy per fraction for 15-20 fractions, augmented by weekly high-dose vertices of 8-15 Gy per fraction for 3-4 fractions, aiming to enhance tumor control and potentially stimulate immune responses.
This study is a multicenter, prospective, randomized controlled phase II clinical trial designed to evaluate the efficacy and safety of Spatially Fractionated Radiation Therapy (SFRT) compared to Conventional Radiation Therapy (CRT) in the treatment of soft tissue sarcoma (STS, minimum tumor diameter ≥5 cm). A total of 106 patients were enrolled and randomized in a 1:1 ratio. The primary endpoint is the objective response rate (ORR) of the target lesion at 3, 6, 9, and 12 months post-radiotherapy, assessed using RECIST 1.1 and Choi criteria. Secondary endpoints include the 1-year local control rate (LC) of the target lesion, progression-free survival (PFS), safety (per CTCAE v5.0). CRT is delivered at 3.0 Gy per fraction for a total of 15-20 fractions. SFRT comprises CRT at 3.0 Gy per fraction for 15-20 fractions, augmented by weekly high-dose vertices of 8-15 Gy per fraction for 3-4 fractions, aiming to enhance tumor control and potentially stimulate immune responses.
Conditions
- Soft Tissue Sarcoma (STS)
Interventions
- RADIATION
-
Spatially Fractionated Radiotherapy
SFRT builds on CRT, administered at 3.0 Gy per fraction for 15-20 fractions, with the addition of weekly high-dose vertices of 8-15 Gy per fraction for 3-4 fractions. It employs Intensity-Modulated Radiation Therapy (IMRT), Intensity-Modulated Proton Therapy (IMPT), or Volumetric Modulated Arc Therapy (VMAT) to create a grid-like pattern of alternating high- and low-dose regions. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
- RADIATION
-
Conventional Radiotherapy
CRT is delivered at 3.0 Gy per fraction for a total of 15-20 fractions, utilizing Intensity-Modulated Radiation Therapy (IMRT) or Intensity-Modulated Proton Therapy (IMPT) techniques, ensuring a target volume dose coverage of at least 90%. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
Sponsors & Collaborators
-
Shandong Cancer Hospital and Institute
lead OTHER
Principal Investigators
-
Jinbo Yue, Doctor · Shandong Cancer Hospital and Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-20
- Primary Completion
- 2027-05-20
- Completion
- 2028-05-20
Countries
- China
Study Locations
More Related Trials
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
NCT06087861 ·Status: RECRUITING ·Phase: PHASE2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
NCT06905132 ·Status: RECRUITING ·Phase: PHASE2
-
Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma
NCT00740597 ·Status: TERMINATED ·Phase: PHASE2
-
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
NCT05577052 ·Status: UNKNOWN ·Phase: NA
-
SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma
NCT02561559 ·Status: UNKNOWN
-
Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk
NCT04562480 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
High Precision RT For Soft-Tissue Sarcoma
NCT01389050 ·Status: COMPLETED ·Phase: PHASE2
-
Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas
NCT04425967 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
NCT02701153 ·Status: RECRUITING ·Phase: NA
-
Feasibility Trial of Preoperative 5-Day Hypofractionated Radiotherapy for Primary Soft Tissue Sarcoma
NCT05776667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
NCT00589121 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT00551369 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Radiosurgery for Soft Tissue Sarcoma
NCT02706171 ·Status: WITHDRAWN ·Phase: NA
-
A Single-center Observational Clinical Trial of Stereotactic Radiotherapy on Metastatic Spinal Tumors Using TomoTherapy
NCT05808998 ·Status: UNKNOWN
-
Efficacy and Toxicity of SCART
NCT06341257 ·Status: WITHDRAWN ·Phase: NA
-
The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors
NCT00001189 ·Status: COMPLETED ·Phase: PHASE2
-
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma
NCT04434989 ·Status: RECRUITING ·Phase: NA
-
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
NCT03989596 ·Status: UNKNOWN ·Phase: PHASE2
-
Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma
NCT07265661 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
NCT06760221 ·Status: RECRUITING ·Phase: NA
-
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
NCT06936748 ·Status: RECRUITING ·Phase: PHASE2
-
TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients
NCT03588403 ·Status: UNKNOWN
-
Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk
NCT03819985 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis
NCT01525745 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer
NCT05034055 ·Status: UNKNOWN ·Phase: PHASE2